Moxibustion combined with acupuncture increases tight junction protein expression in Crohn's disease patients.

Researchers in China studied whether combining moxibustion (a therapy that burns herbs near the skin) with acupuncture could help people with Crohn's disease, a condition that causes chronic inflammation in the digestive tract. The study included 60 patients with mild to moderate Crohn's disease who were divided into two groups: one received herb-partitioned moxibustion plus acupuncture, while the other took mesalazine, a standard medication for Crohn's disease.

The acupuncture and moxibustion group received treatment six times weekly for 12 weeks at specific points including Zusanli (ST36), Tianshu (ST25), and others. Researchers examined intestinal tissue samples to measure proteins called tight junction proteins, which help maintain the intestinal barrier that prevents harmful substances from leaking through the gut wall.

The results showed that both treatments improved intestinal structure, but the moxibustion-acupuncture combination produced better results. This treatment significantly increased all three types of tight junction proteins measured (ZO-1, occludin, and claudin-1), while mesalazine only increased two of them. The moxibustion-acupuncture group showed particularly strong improvement in ZO-1 protein expression compared to the medication group.

These findings suggest that moxibustion combined with acupuncture may help repair the intestinal barrier in Crohn's disease patients by strengthening the connections between intestinal cells. This could reduce inflammation and improve symptoms. The treatment appears to be at least as effective as standard medication for improving intestinal barrier function. If you're considering acupuncture or moxibustion for Crohn's disease, consult with a licensed acupuncturist who has experience treating digestive disorders.

This parallel-controlled trial compared herb-partitioned moxibustion combined with acupuncture (HMA) versus mesalazine in 60 mild-to-moderate Crohn's disease patients (n=30 per group). The HMA protocol utilized alternating point sets six times weekly for 12 weeks: Set A included ST25, RN6, RN9 (moxibustion) and ST36, ST37, LI11, LI4 (acupuncture); Set B included BL23, BL25 (moxibustion) and T1-T6 Jiaji points (acupuncture). Immunohistochemistry and in situ hybridization assessed tight junction protein expression in intestinal biopsies.

Results demonstrated HMA significantly increased expression of ZO-1 (P=0.000), occludin (P=0.021), and claudin-1 (P=0.016) proteins and their mRNAs. Mesalazine increased ZO-1 and occludin but not claudin-1 (P=0.935). Between-group analysis showed HMA produced significantly greater ZO-1 protein (2333.34±352.51 vs 2160.38±307.08, P=0.047) and mRNA expression (2378.17±308.77 vs 2200.56±281.88, P=0.023) compared to mesalazine. Both groups showed improved intestinal morphology, with superior results in the HMA group. Clinical takeaway: HMA appears effective for repairing intestinal epithelial barrier dysfunction in CD through upregulation of tight junction proteins.